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Low weight at birth is associated with subsequent suscep-
tibility to diabetes. Epigenetic modulation is among
the mechanisms potentially mediating this association.
We performed a genome-wide DNA methylation anal-
ysis in placentas from term infants born appropriate-
for-gestational-age (AGA) or small-for-gestational-age
(SGA) to identify new genes related to fetal growth and
neonatal body composition. Candidate genes were vali-
dated by bisulﬁte pyrosequencing (30 AGA, 21 SGA) and
also analyzed in cord blood. Gene expression analyses
were performed by RT-PCR. Neonatal body composition
was assessed by dual X-ray absorptiometry at age 2 weeks.
The ATG2B, NKX6.1, and SLC13A5 genes (respectively re-
lated to autophagy, b-cell development and function, and
lipidmetabolism)were hypermethylated in placenta and cord
blood from SGA newborns, whereas GPR120 (related to
free fatty acid regulation) was hypomethylated in placenta
and hypermethylated in cord blood. Gene expression levels
were opposite to methylation status, and both correlated
with birth weight, circulating IGF-I, and total and abdominal
fat at age 2 weeks. In conclusion, alterations in methylation
and expression of genes involved in the regulation of energy
homeostasis were found to relate to fetal growth and neo-
natal body composition and thus may be among the early
mechanisms modulating later susceptibility to diabetes.
Individuals born small-for-gestational-age (SGA) are at
increased risk for developing insulin resistance, obesity,
metabolic syndrome, and, subsequently, cardiovascular
disease and type 2 diabetes in adulthood (1,2). Growth
restraint before birth is thought to confer such risk, par-
ticularly when followed by excessive weight gain after birth
(3). By the postnatal age of 4 months, SGA infants already
have an altered endocrine-metabolic proﬁle with elevated
concentrations of circulating IGF-I and high–molecular
weight adiponectin (4). These abnormalities are inﬂuenced by
early nutrition and evolve toward a proﬁle that includes more
hepatic and visceral adiposity in childhood (5). The mecha-
nisms underpinning these abnormalities remain poorly
understood.
Epigenetic regulation of the placenta evolves during
preimplantation and progresses further during gestation.
Strictly regulated DNA methylation has a key role in tissue-
speciﬁc gene regulation and transcription; DNA methyl-
ation in CpG islands has been the most investigated target
so far (6). Although DNA methylation has traditionally
been viewed as an epigenetic “silencing” mark, recent ad-
vances suggest that the impact of DNA methylation on
gene expression depends more on the genomic location
of the CpG site (7). An adverse intrauterine environment
can modify placental epigenetic marks and gene expression
proﬁles, resulting in fetal growth restraint (8–10). Differ-
ential patterns of placental and cord blood methylation
and/or expression have been described in selected imprinted
and nonimprinted genes (11,12) in heterogeneous popula-
tions, including preterm infants (11) and growth-restricted
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fetuses from pregnancies complicated by hypertension or
preeclampsia (12). Genome-wide methylation abnormalities
in adipose-derived stem cells from SGA individuals have also
been reported (13).
We tested whether placental and cord blood methyl-
ation and/or expression of genes involved in the regula-
tion of energy homeostasis (which may inﬂuence both
early growth and later diabetes risk) differ between offspring
born appropriate-for-gestational-age (AGA) or SGA after an
uncomplicated, term, singleton pregnancy.
RESEARCH DESIGN AND METHODS
Study Population
The study cohort consisted of 51 mother-placenta-new-
born trios, with postnatal follow-up (Supplementary Fig.
1). Thirty infants were born AGA (17 girls, 13 boys) and
21 SGA (9 girls, 12 boys). The inclusion and exclusion
criteria are detailed in Supplementary Data.
Maternal age at conception, parity, and height, as well as
pregestational weight and BMI [weight (kg)/height (m2)],
were retrieved from clinical records. Gestational age was cal-
culated from last menses and conﬁrmed by ﬁrst-trimester
ultrasound (;10 weeks).
The infant’s weight and length were measured by the
same investigator (G.S.) at birth and at the postnatal age
of approximately 2 weeks. Weight was measured with a
beam balance (Seca, Hamburg, Germany) and length with
a length board, using the mean of three measurements.
DNA Methylation Microarray in Placenta
DNA methylation proﬁling was performed in eight AGA
and eight SGA samples with the Agilent DNA Methylation
array (ID 049738, Agilent Technologies), which examines
27,800 highly informative CpG sites located within the
proximal promoter regions of 14,475 genes. Nearly 100%
of these CpG sites were localized within CpG islands. The
process for isolating methylated DNA from puriﬁed DNA
samples, as well as labeling and hybridization to the
Human DNA Methylation Array, was conducted following
the manufacturer’s protocol (Agilent Microarray Analysis
of Methylated DNA Immunoprecipitation version 1.1,
Agilent Technologies). Brieﬂy, 5 mg of puriﬁed DNA was
sonicated in PBS; DNA fragments were run in a 1.5%
agarose gel and ranged in size from 200 to 1,000 base pairs.
Enrichment of methylated regions was performed using an
antibody against 5-methylcytosine. Enriched and unen-
riched DNA samples were labeled with Cy3 and Cy5, res-
pectively, and hybridized in the microarray. The microarray
chip was then washed and immediately scanned using a
microarray scanner (Model G2505C, Agilent Technologies).
Gene Expression Analysis in Placenta and Cord Blood
Steady-state mRNA levels of GPR120, ATG2B, NKX6.1,
and SLC13A5, as well as the housekeeping gene GAPDH,
were measured using gene-speciﬁc primers (GPR120: for-
ward 59-CTGCCTCTCTGCGTCTTCTT-39, reverse 59-CTCTT
GCATCCAGGAGGTGT-39; ATG2B: forward 59-ATCCCAGC
CTTTTGAAGGAC-39, reverse 59-AGCAAAAGCAGTGGGTT
GAT-39; NKX6.1: forward 59-CTTCTGGCCCGGAGTGAT-39,
reverse 59-CCCGCCAAGTATTTTGTTTG-39; SLC13A5: for-
ward 59- CCTGCTGGATTGGAAGGTAA-39, reverse 59-CAC
TCAGTGAACACGGCAAC-39; GAPDH: forward 59-GTCAG
TGGTGGACCTGACCT-39, reverse 59-TGCTGTAGCCAAAT
TCGTTG-3) and SYBR Green PCR Master Mix (Applied Bio-
systems, Foster City, CA). PCR reactions were performed us-
ing a 7500 Real-Time PCR System (Applied Biosystems) by
mixing 1 mL of cDNA (20 ng) with 24 mL of reaction mixture
(14 mL 2 3 SYBR Green I Master Mix buffer), 2 mL forward
primer (2.5 mmol/L), 2 mL reverse primer (2.5 mmol/L), and
6 mL of nuclease-free water. Relative expression was then
calculated according to the 2-DCt method (14).
The details regarding cord blood and placenta collec-
tion, DNA extraction and modiﬁcation, microarray data
preprocessing, validation by bisulﬁte pyrosequencing, RNA
extraction, and retrotranscription, as well as the assays and
neonatal body composition assessment procedures, are pro-
vided in the Supplementary Data.
Statistics and Ethics
Statistical analyses were performed using SPSS Statistics
23.0 (IBM Corp., Armonk, NY). Unpaired t test was used to
study differences between AGA and SGA subgroups. Corre-
lation and stepwise multiple regression analysis were used
to study how methylation status and expression levels in
placenta and cord blood were associated with auxological
and body composition parameters. Covariance analysis was
used to adjust for sex, gestational age, type of delivery, and
pregestational BMI. The level of signiﬁcance was set at P ,
0.05.
The study was approved by the Institutional Review Board
of Hospital Sant Joan de Déu at the University of Barcelona.
Written informed consent was obtained before delivery.
RESULTS
Maternal and Offspring Characteristics
Table 1 summarizes the anthropometric parameters in
the mothers and newborns by birth weight subgroup.
The delivery rate by cesarean section was not different
between the AGA and SGA subgroups (13% vs. 19%, re-
spectively). SGA infants displayed lower circulating levels
of insulin and IGF-I in cord blood and less fat and lean
mass at age 2 weeks, as expected, while their mothers
were shorter and had a lower pregestational weight and
BMI (14).
Gene Ontology and Functional Pathway Analysis
We identiﬁed 409 genes differentially methylated in SGA
newborns (false discovery rate , 0.1) (Supplementary
Table 1). The gene ontology analysis disclosed that most
of them were involved in the regulation of metabolic
processes, DNA binding and transcription, and biosynthe-
sis of macromolecules (Supplementary Table 2). The Kyoto
Encyclopedia of Genes and Genomes (KEGG) software iden-
tiﬁed enriched numbers of epigenetic changes in 11 canonical
pathways, the most signiﬁcant being those related to cell
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development and function, lipid metabolism, autophagy,
and signaling (Table 2). The top-ranked hyper- and hypome-
thylated genes in these pathways (n = 39) are listed in
Supplementary Tables 3 and 4, respectively. Because valida-
tion of all 39 genes by pyrosequencing was not feasible
(costly and technically complex), in accordance with the
study purpose we selected those genes (n = 8) that were
relevant to the regulation of glucose and lipid metabolism;
of those, three were hypomethylated (MAPK8IP1, CAMK4,
and GPR120) and ﬁve were hypermethylated (ATG2B,
KLF11, NKX6.1, NRIP1, and SLC13A5) in placentas of SGA
newborns (Supplementary Tables 3 and 4).
Differentially Methylated Genes in Placenta
and Cord Blood
Validation of DNA methylation patterns by pyrosequenc-
ing demonstrated that ATG2B, NKX6.1, and SLC13A5
were hypermethylated in SGA placenta (P , 0.02, P ,
0.008, and P , 0.0001, respectively, vs. AGA) and SGA
cord blood (all P , 0.0001), while GPR120 was hypome-
thylated in SGA placenta (P = 0.0006) and hypermethy-
lated in SGA cord blood (P , 0.0001) (Figs. 1 and 2). The
differences in methylation were maintained after adjusting
for sex, gestational age, type of delivery, and pregestational
BMI. Pyrosequencing analysis failed to demonstrate differ-
ences in methylation status in MAPK8IP1, CAMK4, KLF11,
and NRIP1 genes.
Expression of Validated Genes in Placenta
and Cord Blood
Expression levels of ATG2B, NKX6.1, SLC13A5, and
GPR120 in placenta and cord blood were opposite to their
methylation status (all P# 0.004 in placenta; all P# 0.01
in cord blood) (Figs. 1 and 2). The differences in gene
expression were maintained after adjusting for sex, ges-
tational age, type of delivery, and pregestational BMI.
Correlation and multiple regression analyses between
genetic and endocrine-metabolic data are provided in the
Supplementary Data.
DISCUSSION
We identiﬁed differential methylation proﬁles in placenta
and cord blood from SGA infants in 18 CpG sites along
the ATG2B, NKX6.1, SLC13A5, and GPR120 genes—all
nonimprinted—and report for the ﬁrst time associations
with birth weight, endocrine-metabolic markers, and neonatal
body composition. Neither the differences in methylation
and expression nor the associations with growth and
Table 1—Auxological and clinical parameters in the studied infants and their mothers
AGA,
N = 30
SGA,
N = 21 P value
Mothers
Age (years) 31.8 6 1.1 31.8 6 1.0 NS
Height (cm) 164 6 0.01 159 6 0.01 0.01
Weight (kg) 66.0 6 2.6 53.6 6 1.6 0.0005
BMI (kg/m2) 24.6 6 0.9 21.1 6 0.6 0.003
Pregnancy weight gain (kg) 13.4 6 0.9 11.5 6 0.7 NS
Primiparous (%) 57 76 NS
Cesarean section (n [%]) 4 (13) 4 (19) NS
Singleton newborns
Sex (% female) 57 43 NS
Gestational age (weeks) 40.2 6 0.2 38.7 6 0.3 0.0008
Birth weight (kg) 3.3 6 0.1 2.3 6 0.1 ,0.0001
Birth weight Z-score 0.1 6 0.1 22.3 6 0.1 ,0.0001
Birth length (cm) 50.6 6 0.3 45.6 6 0.5 ,0.0001
Birth length Z-score 0.2 6 0.1 21.9 6 0.2 ,0.0001
Placental weight (kg) 0.60 6 0.02 0.51 6 0.03 0.022
Endocrine-metabolic variables at birth
Glucose (mmol/L) 4.4 6 0.2 4.5 6 0.4 NS
Insulin (pmol/L) 27.8 6 3.5 17.4 6 2.1 0.009
IGF-I (nmol/L) 0.09 6 0.01 0.06 6 0.01 0.001
HMW adiponectin (mg/L) 43 6 3 41 6 3 NS
Body composition at 2 weeks
Weight gain since birth (g) 184 6 53 310 6 60 NS
Length gain since birth (cm) 1.7 6 0.2 2.2 6 0.6 NS
Bone mineral density (g/cm2) 0.27 6 0.01 0.24 6 0.01 0.026
Bone mineral content (g) 94.4 6 2.2 69.9 6 2.8 ,0.0001
Fat mass (%) 18 6 1 16 6 1 0.04
Fat mass (g) 696 6 39 467 6 38 0.0001
Abdominal fat (%) 4.1 6 0.2 3.3 6 0.2 0.01
Abdominal fat (g) 29 6 2 16 6 3 0.0007
Lean mass (%) 82 6 1 83 6 1 NS
Lean mass (g) 3,110 6 55 2,279 6 68 ,0.0001
Data are mean 6 SEM unless otherwise indicated. HMW, high molecular weight; NS, not signiﬁcant.
diabetes.diabetesjournals.org Díaz and Associates 781
endocrine-metabolic markers were attributable to differences
in maternal BMI or infants’ gestational age, sex, or delivery
route. The ﬁnding that the methylation and the expression of
highlighted genes mirror each other, in both placenta and
cord blood, suggests that the expression of those genes is
mainly under epigenetic control, presumably inﬂuenced by
multiple maternal and environmental factors, most of which
remain to be identiﬁed.
Hypermethylation and downregulation of ATG2B
(autophagy-related 2B) in placenta and cord blood were
associated with smaller size at birth and lower fat mass.
Autophagy is critical in the maintenance of maternal-fetal
material exchange during placental development, in sur-
vival immediately after birth (15), and in cell differen-
tiation, including adipogenesis (16). In SGA infants,
decreased autophagy resulting from downregulation of
ATG2B—thus compromising the nutrient supply—could
be among the mechanisms accounting for prenatal growth
restraint.
NKX6.1 (NKX6 homeodomain 1)—a transcription factor
known to be involved in pancreatic differentiation and b-cell
homeostasis—was hypermethylated and downregulated
in placenta and cord blood from SGA infants and was
associated with birth weight and neonatal fat mass. In the
pancreas, NKX6.1 is exclusively expressed in b-cells and is
required for prenatal b-cell development and function and
postnatal b-cell expansion (17). In placenta, it remains to be
studied whether the epigenetically controlled expression of
NKX6.1 is a modulator of nutrient transfer and thus per-
haps an indirect modulator of fetal b-cell development, in-
sulin secretion, and fat mass.
Mammalian Indy homolog (SLC13A5, mIndy) encodes
for a sodium-coupled citrate transporter that is mainly
expressed in hepatocytes and serves as a link between car-
bohydrate catabolism and lipogenesis. Loss of SLC13A5
augments energy expenditure and hepatic fat oxidation
and attenuates hepatic lipogenesis, reducing overall growth
(18). SLC13A5 was hypermethylated and downregulated in
SGA placenta and cord blood. These ﬁndings align well with
the knowledge that SGA infants have less adipose tissue
and are more insulin sensitive than AGA infants, not only
in early infancy but, if breastfed, also in late infancy (19).
Reduced expression of SLC13A5 may conceivably be a pro-
gramming mechanism attempting to protect those fetuses
from excessive fat accumulation and impaired insulin ac-
tion early during spontaneous catch-up.
Table 2—Differentially methylated genes involved in KEGG pathways
Canonical pathway P value
Methylation
status Gene symbol
Cell development
and function
3.7E-04 Hyper PHOX2B, NDEL1, GFOD1, SMAD7, KCNK13, EFNA1, CHRM2,
CNTN4, NKX2–5, NKX3–2, NKX6.1, LMO2, PYGO2
Lipid metabolism 4.0E-04 Hypo SOAT1, LYPLA2P1, GPR120, SORL1, MAPK8IP1, ECHDC2, PEX1,
LYPLA2, ATG2B, HSD17B4
Autophagy 5.4E-04 Hyper DRAM1, ATG2B, AMBRA1, SOGA1
Cellular signaling 6.6E-04 Hypo EIF2AK1, SLK, CAMK4, MAPK13, PAK4, CHKB, PRKG1, ALK,
STARD3NL, PAPSS1, AKT3
Cation channel activity 1.3E-03 Hyper CALHM2, SCN3B, SLC24A2, SLC13A5, KCNK13
Regulation of immunity 1.7E-03 Hyper STAT5B, ICOSLG, PTPN22, RARA
Endoplasmic reticulum
metabolism
2.4E-03 Hyper SOAT1, DERL2, SPTLC1, CLSTN2, LOC729316, RTN2, SYNE1,
NDEL1, LRP10, LARGE, C3ORF57, FAM156A, GNAS, FAM156B,
EIF2AK1, POM121C, KPNA4, EDA, DLG1
DNA binding 2.4E-03 Hypo FLYWCH1, HIST1H2B1, HIST4H4, HIST1H4K, LOC100045887,
NFKB2, SRF, GM11275, ARNT, HOXA3, LOC674678, HIST1H4A,
HIST1H4B, NKX3–2, POU3F4, SRRM1, HIST1H4F, HIST1H4C,
HIST1H4D, HIST1H4I, LBR, HIST1H4J, HIST1H4H, ZBTB48, CEBPD,
NEUROG1, ZFP3, MECOM, HIST2H4, UHRF2, SFPQ, TOP3B
Transcription regulation 3.2E-03 Hyper ZNF583, POU6F2, STAT5B, ZNF827, RHOQ, HSBP1, CNOT4, ZNF343,
ZGPAT, GTF2H2C, BRPF1, ZNF182, ZNF436, GTF2H2C, ZNF680,
ZFP90, PSMC3IP, RARA, SOX17, FOXB1, GATAD1, MBD3L1,
PHOX2B, RCOR3
Transcription regulation 3.2E-03 Hypo SCAI, JUNB, MCM5, NRIP1, GTF2H2B, ZNF500, ZNF234, TAF11,
PRDM9, MED18, LIN54, EDA, HMX3, ZNF468, GPBP1L1, SCML1,
NFYC, MYBL1, HOXA1, THAP1, NKX2–5, MLLT3, SMAD7, KLF11,
SOX30, TFCP2,STAT1, FOXP4, NKX6.1, ZNF22, ZNF212, DR1, NARFL,
FMR1, SFPQ, TOP3B
Apoptosis 3.7E-03 Hyper FAM176A, DOCK1, LTBR, AIMP2, STAG3L3, FAM82A2, KLF11, PAK1
Protein interaction 8.4E-03 Hyper DOCK1, DOCK5, ABI1, SKAP2, EPS8L1, RASA1, DLG1
Pathways are arranged (top to bottom) according to P value. The genes in boldface type (n = 39) display the lowest (top-ranked)
individual P values.
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GPR120, also known as free fatty acid receptor
4 (FFAR4), is a lipid sensor that regulates whole-body
energy homeostasis in humans and rodents, mediating
insulin-sensitizing effects in vivo by repressing inﬂam-
mation (20). GPR120 activation indirectly stimulates
pancreatic insulin secretion by inducing the release of
glucagon-like peptide 1 from the gut (21). In this study,
GPR120 was found to be hypomethylated and hyperex-
pressed in SGA placenta. The human placenta expresses
GPR120 mainly in the microvillous membrane of the
syncytiotrophoblast (22), where it presumably transfers
unsaturated long-chain fatty acids from the maternal
circulation into the syncytiotrophoblast rather than into
the fetal circulation. In contrast, GPR120 was hyperme-
thylated and hypoexpressed in cord blood of SGA infants,
who have a reduced fat mass across early infancy (4).
Interestingly, GPR120 is thought to be a key contributor
to adipocyte differentiation in the critical window of adi-
pogenesis (23).
This preliminary study is the ﬁrst to associate epigenetic
regulation of nonimprinted genes with size at birth and
markers of endocrine-metabolic homeostasis and neonatal
body composition in healthy term AGA and SGA infants.
Study limitations include the small sample size, the lack
Figure 1—Methylation (top) and expression levels (bottom) of validated genes in placentas from AGA infants (n = 30) or SGA infants (n =
21). Values are mean 6 SEM. ATG2B, NKX6.1, and SLC13A5 were hypermethylated, whereas GPR120 was hypomethylated, in SGA
infants. Expression levels of ATG2B, NKX6.1, SLC13A5, and GPR120 were opposite to their methylation status. *P < 0.05, **P < 0.01,
***P < 0.0001 vs. AGA.
Figure 2—Methylation (top) and expression levels (bottom) of validated genes in cord blood from AGA infants (n = 30) or SGA infants (n =
21). Values are mean 6 SEM. ATG2B, NKX6.1, SLC13A5, and GPR120 were hypermethylated in SGA infants. Expression levels of ATG2B,
NKX6.1, SLC13A5, and GPR120 were opposite to their methylation status. *P < 0.05, **P < 0.01, ***P < 0.0001 vs. AGA.
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of adjustment for cell composition in placenta/cord blood
(24), the inﬂuence of maternal genetics on placental gene
expression, the potential underrepresentation of differen-
tial methylation in CpG islands (25), and the inability to
obtain—for ethical reasons—target tissues for the assess-
ment of tissue-speciﬁc DNA methylation/expression. The
strengths include the strict inclusion criteria (leading to
distinct AGA and SGA populations and avoiding perinatal
confounders) and the parallel assessments of placenta/cord
blood pairs.
In conclusion, in SGA placenta and cord blood we iden-
tiﬁed differential methylation and expression patterns of
genes involved in the regulation of glucose homeostasis
and lipid metabolism. These epigenetic variations may in-
ﬂuence fetal growth, early body composition, and lifelong
diabetes risk.
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